Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
InSphero Accelerates Global Growth and US Expansion with Acquisition of PhenoVista Biosciences
Schlieren, Switzerland - May 20, 2026 Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing InSphero, the global leader in advanced 3D in vitromodels and services for drug safety and efficacy testing, today announced the acquisition of California-based...
Mabylon Reports Positive Phase Ia Results in MY006 Peanut Allergy Trial and Initiates Phase Ib Patient Part of the Study; Advances Tree Pollen Allergy Program MY010 toward Clinical Development
Schlieren/Zurich, Switzerland, May 19, 2026 - Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. Mabylon also announced the initiation of dosing...